Related Experiment Video
Updated: Aug 10, 2026
09:51
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
Soluble IL-4 receptor, potential for therapeutic and prophylactic intervention
1Institute for Clinical Microbiology and Immunology, University of Erlangen-Nürnberg, Germany.
Behring Institute Mitteilungen
|December 1, 1994
Summary
Recombinant soluble interleukin-4 receptor (sIL-4R) treatment protected mice against cutaneous leishmaniasis by promoting a Th1 immune response and reducing parasite load. This therapy offers durable resistance against reinfection.
Area of Science:
- Immunology
- Parasitology
- Molecular Biology
Background:
- Cell-mediated immunity, particularly T helper (Th) cell responses (Th1/Th2), dictates disease outcomes in infections.
- Interleukin-4 (IL-4) is crucial in driving Th2 responses and disease progression in murine cutaneous leishmaniasis.
- A naturally occurring IL-4 antagonist, soluble IL-4 receptor (sIL-4R), binds IL-4 with high affinity.
Purpose of the Study:
- To investigate the immunomodulatory and therapeutic potential of recombinant sIL-4R in murine cutaneous leishmaniasis.
- To assess the impact of sIL-4R treatment on disease progression, parasite load, and immune cell differentiation.
Main Methods:
- BALB/c mice infected with Leishmania major were treated with recombinant sIL-4R during the immune response onset.
- Evaluated clinical resistance, parasite burden, cytokine profiles (Th1/Th2 bias), and long-term resistance to reinfection.
Main Results:
- sIL-4R treatment conferred clinical resistance to Leishmania major infection.
- Treatment led to a significant reduction in parasite load.
- Cytokine patterns shifted towards a protective Th1 response, and durable resistance against reinfection was established.
Conclusions:
- Recombinant sIL-4R demonstrates significant therapeutic capacity for murine cutaneous leishmaniasis.
- Targeting IL-4 with sIL-4R effectively modulates the immune response towards a protective Th1 phenotype.
- sIL-4R represents a promising strategy for treating leishmaniasis and preventing reinfection.
Related Concept Videos
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:29Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...